.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF05_Lamivudine.Lamivudine .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF05_Lamivudine.Lamivudine| name: | Lamivudine |
| ATC code: | J05AF05 | route: | oral |
| n-compartments | 1 |
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV infection and hepatitis B virus (HBV) infection. It is an approved antiviral drug widely used as part of combination therapy for HIV/AIDS and also for chronic HBV infection.
Pharmacokinetics in healthy adult volunteers after oral administration.
Wen, H, et al., & Zhang, L (2022). Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. Expert review of clinical pharmacology 15(5) 647–655. DOI:10.1080/17512433.2022.2078306 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35938476
Bekker, A, et al., & Cressey, TR (2024). Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study. The Journal of antimicrobial chemotherapy 79(10) 2570–2574. DOI:10.1093/jac/dkae259 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39092932
Moore, KH, et al., & Bartlett, JA (1999). Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrobial agents and chemotherapy 43(12) 3025–3029. DOI:10.1128/AAC.43.12.3025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10582904